A detailed history of Exane Derivatives transactions in Emergent Bio Solutions Inc. stock. As of the latest transaction made, Exane Derivatives holds 39 shares of EBS stock, worth $369. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39
Previous 1,245 96.87%
Holding current value
$369
Previous $51,000 98.04%
% of portfolio
0.0%
Previous 0.02%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 12, 2022

SELL
$27.42 - $43.63 $33,068 - $52,617
-1,206 Reduced 96.87%
39 $1,000
Q1 2022

Apr 22, 2022

SELL
$36.48 - $52.22 $15,503 - $22,193
-425 Reduced 25.45%
1,245 $51,000
Q4 2021

Jan 28, 2022

SELL
$33.11 - $55.01 $11,720 - $19,473
-354 Reduced 17.49%
1,670 $72,000
Q3 2021

Oct 26, 2021

SELL
$50.07 - $66.05 $16,673 - $21,994
-333 Reduced 14.13%
2,024 $101,000
Q2 2021

Jul 28, 2021

SELL
$56.61 - $80.46 $43,533 - $61,873
-769 Reduced 24.6%
2,357 $148,000
Q1 2021

Apr 30, 2021

SELL
$86.23 - $125.19 $109,770 - $159,366
-1,273 Reduced 28.94%
3,126 $290,000
Q4 2020

Jan 27, 2021

BUY
$79.17 - $111.47 $348,268 - $490,356
4,399 New
4,399 $394,000

Others Institutions Holding EBS

About Emergent BioSolutions Inc.


  • Ticker EBS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 49,861,500
  • Market Cap $473M
  • Description
  • Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emergi...
More about EBS
Track This Portfolio

Track Exane Derivatives Portfolio

Follow Exane Derivatives and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

News

Stay updated on Exane Derivatives with notifications on news.